Verdier Eye Center is dedicated to providing our patients with the most advanced treatments and advancing the scientific understanding of eye diseases.
The physicians are constantly evaluating developing treatments for their potential impact eye diseases that affect our patients.
These treatments undergo rigorous testing for efficacy and safety, and those few with the most potential make it to clinical trials. Testing at this stage requires centers that can diagnose, treat, and monitor diseases at the highest level. Bringing these treatments to our patients is an essential service at Verdier Eye Center.
Please continue reading to learn more about our current research protocols and activities.
The study objective is to evaluate whether or not prolonged suppressive oral antiviral treatment with Valacyclovir 1000 mg/daily (two 500mg pills qam) reduces complications of HZO, in immunocompetent patients, compared to standard care without prolonged systemic antiviral treatment. The study is also monitoring post-herpetic neuralgia during the 18-month study period.
This double-masked multi-center trial will evaluate the association of diabetes in the cornea donor with transplant success and loss of endothelial cells one year following Descemet membrane endothelial keratoplasty (DMEK). Study eyes will be assigned to receive either a cornea from a donor without diabetes or a cornea from a donor with diabetes.
A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration with Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Descemetorhexis in Subjects with Fuchs Endothelial Corneal Dystrophy.
A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration with Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Subjects with Fuchs Endothelial Corneal Dystrophy.
To establish the functional state of the corneal endothelium in Fuchs disease before and after DMEK (Descemet Membrane Endothelial Keratoplasty) and to refine a preliminary model that predicts corneal improvement after DMEK for Fuchs disease by using special tomography imaging parameters.
A Standardized, Multi-centered, Observational Study for subjects with FECD. No investigational product will be used. Study visits will consist of Screening/Baseline (Day 1) - Blood Specimen collection within 2 weeks of Baseline visit, followed by a 12-month and 24-month visit. Primary goal being to characterize the natural history and clinical management of FECD.
A Phase-1, prospective, multi-center, open-label, dose escalation study to assess the safety and tolerability of EO2002 with and without endothelial brushing or descemet stripping in the treatment of corneal edema.
This is a multi-site, randomized, clinical trial with the primary objective to determine whether the intraocular infection (endophthalmitis) rate following cataract surgery is lower with an antibiotic (moxifloxacin) commonly used in ophthalmology injected into the anterior chamber (intracameral) versus topical moxifloxacin applied externally as eye drops.
/
The study aims to determine whether corneal tissue that undergoes ex vivo CXL by the eye bank results in better vision and less keratometric astigmatism. We would be including patients that undergo their first PKP or DALK with a history of keratoconus.
